Developing antimicrobial smart plasters for diabetic foot ulcers
Chronic wounds, including diabetic foot ulcers, can remain unhealed for months or years. Antibiotic-resistant bacteria make infections harder to treat, while biofilms shield bacteria from antibiotics and immune responses. Resistant wound infections can prolong hospital stays and, in severe cases, lead to amputation.
ChainPeptides develops antimicrobial peptides for wound-care devices and a smart plaster for diabetic foot ulcers. The planned dressing combines antimicrobial protection with infection sensing to help patients and clinicians manage wounds.
What stands out about ChainPeptides
Reports granted patents covering three antimicrobial peptides in the USA, several EU countries, Japan, China and India.
Demonstrated in-vitro activity of chain peptides against gram-positive and gram-negative bacteria in laboratory experiments.
Founder Tejesvi Mysore is a PhD and adjunct professor with research experience directly linked to antimicrobial peptide development.
Tejesvi Mysore founded Chain Antimicrobials in 2017 before establishing ChainPeptides in 2022 to focus on chronic wound care.
Supported by OYSTER Incubator and listed among its 2026 teams developing health and life-sciences solutions.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.